Abstract
Bodyweight has been shown to influence anidulafungin exposure, but data from obese patients are lacking. We determined anidulafungin pharmacokinetics (100-mg single dose) in eight morbidly obese subjects (body mass index >40 kg/m2). Anidulafungin exposure was on average 32.5 % lower compared with the general patient population, suggesting dose increases may be required in this population.
Original language | English |
---|---|
Pages (from-to) | 1289-1294 |
Number of pages | 6 |
Journal | Clinical Pharmacokinetics |
Volume | 55 |
Issue number | 10 |
DOIs | |
Publication status | Published - 1 Oct 2016 |
Externally published | Yes |